Goldman Sachs Maintains Neutral on NewAmsterdam Pharma Co, Raises Price Target to $37
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Asad Haider maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral and raises the price target from $30 to $37.
Goldman Sachs analyst Asad Haider maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral and raises the price target from $30 to $37.